Total results1,200
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 5HT7R | P34969 | 5-hydroxytryptamine receptor 7 (5-HT-7) (5-HT7) (5-HT-X) (Serotonin receptor 7) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Alzheimer diseaseAttention deficit hyperactivity disorderBipolar disorder | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 2 | 0.53 | ||
| AA2BR | P29275 | Adenosine receptor A2b | 7 | Alzheimer diseaseAsthmaBreathing abnormality | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 | |||
| ACE | P12821 | Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (Dipeptidyl carboxypeptidase I) (Kininase II) (CD antigen CD143) [Cleaved into: Angiotensin-converting enzyme, soluble form] | Candidate cardiovascular disease genesCD markersDisease related genes | 1 | AsthmaCardiovascular diseaseChronic kidney disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 | ||
| ACHA3 | P32297 | Neuronal acetylcholine receptor subunit alpha-3 | Disease related genesFDA approved drug targetsPredicted intracellular proteins | 4 | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 2 | 0.53 | |||
| ACHA5 | P30532 | Neuronal acetylcholine receptor subunit alpha-5 | FDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins | 4 | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 2 | 0.53 | |||
| ACM3 | P20309 | Muscarinic acetylcholine receptor M3 | Disease related genesFDA approved drug targetsG-protein coupled receptors | 7 | Abnormal micturitionAlzheimer diseaseAsthma | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 2 | 0.53 | ||
| ADA2C | P18825 | Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Acute diabetic complicationAlzheimer diseaseAsthma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 | ||
| ANO2 | Q9NQ90 | Anoctamin-2 (Transmembrane protein 16B) | Predicted membrane proteinsTransporters | 8 | Clinical-translation mediationFusion and delivery mediation | 2 | 0.53 | |||
| ANO6 | Q4KMQ2 | Anoctamin-6 (Small-conductance calcium-activated nonselective cation channel) (SCAN channel) (Transmembrane protein 16F) | Disease related genesHuman disease related genesPotential drug targets | 10 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 | |||
| ANO9 | A1A5B4 | Anoctamin-9 (Transmembrane protein 16J) (Tumor protein p53-inducible protein 5) (p53-induced gene 5 protein) | Predicted membrane proteinsTransporters | 8 | Clinical-translation mediationFusion and delivery mediation | 2 | 0.53 |